Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Atzirut X is a botanical stimulant laxative product developed and marketed by the Israeli pharmaceutical company CTS. It is indicated for the short-term relief of occasional constipation. The formulation is a combination of two plant extracts: Senna (*Cassia angustifolia*) and Buckthorn (*Rhamnus frangula*). These extracts contain anthraquinone glycosides, such as sennosides and glucofrangulins, which act as prodrugs. Upon reaching the colon, they are hydrolyzed by bacterial enzymes into active metabolites like rheinanthrone. These metabolites stimulate the myenteric plexus (Auerbach's plexus) to increase intestinal peristalsis and inhibit the Na+/K+-ATPase pump in the intestinal wall, which reduces water and electrolyte absorption and promotes fluid secretion into the lumen. The combined effect softens the stool and facilitates bowel evacuation. Atzirut X is registered as an over-the-counter (OTC) pharmaceutical drug in Israel.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Atzirut X.